Peter Steyger

Our Sincere Thanks  to Peter Steyger, Ph.D.

HHF is dependent on and incredibly grateful to the clinicians and researchers like Peter who volunteer their time and expertise to reviewing grant applications, overseeing the Emerging Research Grants program, and informing our mission as the largest private, nonprofit funder of hearing and balance research in the U.S. 

Print Friendly and PDF

BLOG ARCHIVE

Moving Toward a Future Free of Drug-Induced Hearing Loss

OHSU_Peter_Steyger.jpg

A special publication orchestrated by five of the nation’s leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents—how it occurs, how to treat it, and how to prevent it.

A free e-book comprising 23 scientific articles from 93 authors, “Cellular Mechanisms of Ototoxicity” was published by Frontiers in Cellular Neuroscience in March 2018. “We’re trying to elevate ways for the human population to avoid losing this important sensation for experiencing and communicating with the world around us,” says co-editor Peter Steyger, Ph.D. (1995–96 ERG), a professor of otolaryngology–head and neck surgery in the Oregon Health & Science University (OHSU) School of Medicine. A member of HHF’s Council of Scientific Trustees, Steyger lost hearing at age 14 months after being treated with antibiotics for meningitis.

“Ototoxicity is a threat to hearing at any age, and hearing loss remains a significant side effect of chemotherapy,” says co-editor Jian Zuo, Ph.D., of St. Jude Children’s Research Hospital in Memphis, Tennessee. Additional editors included experts from the Department of Defense Hearing Center of Excellence and the National Institute on Deafness and Other Communication Disorders. —OHSU News

Print Friendly and PDF

BLOG ARCHIVE

Moving Toward a Future Free of Drug-Induced Hearing Loss

By Erik Robinson

A new special publication orchestrated by five of the nation’s leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents—how it occurs, how to treat it, and how to prevent it.

HHF Council of Scientific Trustees member Peter Steyger, Ph.D., and colleagues produced a special Frontiers in Cellular Neuroscience publication on the topic of ototoxicity.

HHF Council of Scientific Trustees member Peter Steyger, Ph.D., and colleagues produced a special Frontiers in Cellular Neuroscience publication on the topic of ototoxicity.

The compilation was published online as a special research topic by the journal Frontiers in Cellular Neuroscience on March 5, 2018. It includes both original research and focused reviews. The Pharmaceutical Interventions for Hearing Loss Working Group organized the effort at the behest of the Department of Defense (DoD) Hearing Center of Excellence.

“We’re trying to elevate ways for the human population to avoid losing this important sensation for experiencing and communicating with the world around us,” says coauthor Peter Steyger, Ph.D., a professor of otolaryngology/head and neck surgery in the Oregon Health & Science University (OHSU) School of Medicine, and a member of Hearing Health Foundation’s Council of Scientific Trustees.

“Ototoxicity is a threat to hearing at any age and hearing loss remains a significant side effect of chemotherapy. This review highlights how far we’ve come in understanding that threat and provides us with a roadmap for developing more effective ways to recognize and address the problem,” adds coauthor Jian Zuo, Ph.D., of the department of developmental neurobiology at St. Jude Children’s Research Hospital in Memphis, Tennessee.

In people, hearing cells don’t regenerate so the loss is irreversible. That’s why it is crucial to understand the mechanisms that affect hearing and how to prevent loss of hearing, Steyger says. The introductory editorial, “Moving Toward a Future Free of Ototoxicity,” highlights the latest scientific research exploring how certain pharmaceuticals damage the inner ear while others can protect it. It also highlights the need for better monitoring and detection of hearing loss over time, especially among patients being treated with antibiotics.

Steyger, who lost hearing as a child after being treated with antibiotics for meningitis when 14 months old, noted that hearing loss affects a surprisingly large proportion of the population—rising from an estimated 1 in 500 newborns to as many as half of all people age 75 or older. The research encapsulated in the new e-book includes 23 scientific articles from 93 authors and represents the state of the science in both prevention and treatment of ototoxicity hearing loss. (The e-book is available to all, free of charge.)

“This compilation will help to propel our knowledge forward and underscore the need to better understand the dangers of ototoxicity. The DoD Hearing Center of Excellence is honored to host and mobilize this important effort,” says coauthor Carlos Esquivel, M.D., a neurotologist and chief medical officer in the Clinical Care, Rehabilitation, and Restoration Branch of the DoD Hearing Center of Excellence at Joint Base San Antonio in Texas.

In addition to Steyger, Zuo, and Esquivel, the publication’s editors include Lisa Cunningham, Ph.D., of the National Institute on Deafness and Other Communication Disorders, and Kelly Watts, Au.D., of the DoD Hearing Center of Excellence.

This originally appeared in OHSU News and was republished with permission. 

Print Friendly and PDF

BLOG ARCHIVE